Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Psychiatry Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Psychiatry Other
    FDA Requests Boxed Warnings on Conventional Antipsychotic Drugs - (DGNews)
    Pramlintide-Related Improvements in Diabetes Benefit Patients' Psyche: Presented at ADA - (DGDispatch)
    Health Canada Approves New Treatment for Bipolar Mania - (DGNews)
    Report Confirms Increased Risk of Smoking, Substance Abuse in Bipolar Adolescents - (DGNews)
    Short-Term Antipsychotics in Older Adults With Dementia Associated With Serious Adverse Events - (DGNews)

    News archive

     Recent webcasts/CME - Psychiatry Other
    • Dementia in Hispanic Americans: The Reasons Behind the Risk
    • Prevalence and Associated Factors for Suicidal Ideation and Behaviors in Obsessive-Compulsive Disorder
      Delirium Update
      The Pharmacist's Role in Breaking the Cycle of PMDD
      Understanding Autism: The Role of the Pharmacist in the Management of Autism

      Webcasts/CME archive

       Recent cases - Psychiatry Other
        Factitious Lymphoedema as a Psychiatric Condition Mimicking Reflex Sympathetic Dystrophy: A Case Report
        Topiramate-Induced Psychosis in Two Members of the One Family: A Case Report
        Childhood Autism in a 13 Year Old Boy with Oculocutaneous Albinism: A Case Report
        Unexpected Depletion in Plasma Choline and Phosphatidylcholine Concentrations in a Pregnant Woman with Bipolar Affective Disorder Being Treated with Lithuim, Haloperidol and Benztropine: A Case Report
        Recognizing Thyrotoxicosis in a Patient with Bipolar Mania: A Case Report

        Cases archive
          




        my personal edition > psychiatry other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Long-Term Safety Of Atomoxetine In The Treatment Of Attention Deficit Hyperactivity Disorder: Presented at WCP

        By Bruce Sylvester
        Special to DG News

        YOKOHAMA, JAPAN -- August 29, 2002 -- Long-term use of atomoxetine in pediatric attention deficit hyperactivity disorder (ADHD) is safe and well-tolerated, researchers report.

        The results of an open-label extension study led by M.Y. Hill of Eli Lilly and Company, Indianapolis, Indiana, United States, were presented at the 12th World Conference of Psychiatry in Yokohama, Japan.

        Researchers enrolled 325 subjects, 266 males, 59 females, aged from seven to 17 years old. Only patients from previous atomoxetine trials were allowed to enroll in this long-term study. All met DSM-IV criteria for ADHD from their previous atomoxetine trial.

        The ADHD subtype profile was: hyperactive/impulsive (4 or 1.2 percent), inattentive (62 or 19.1 percent) and combined (259 or 79.7 percent)

        "The subjects had no serious medical illness, comorbid psychosis or bipolar disorder, history of seizure disorder, or ongoing use of psychoactive medications other than the study drug," the authors wrote.

        The mean number of days on open-label, continuation therapy was 313. One hundred and forty two subjects completed one year.

        The researchers assessed tolerability and safety of long-term treatment using data on discontinuations, adverse events, ECG data, weight, height, and vital signs.

        A slight increase was noted from baseline to endpoint in mean diastolic blood pressure (3.6 mm Hg) and pulse (3.9 bpm). Mean weight increased (2.6 kg) from baseline to endpoint, as did mean height (4.4 cm).

        The most commonly observed adverse events (headache, rhinitis, abdominal pain, pharyngitis and vomiting) and those associated with atomoxetine therapy (decreased appetite and weight loss) decreased over time. Twelve of the subjects (3.7 percent) left the trial due to an adverse event.

        "A clinically nonsignificant decrease of 4.8msec in mean Fridericia corrected QT interval from baseline-to-endpoint was observed," the investigators reported.

        The authors concluded that, "Overall, atomoxetine was well tolerated in this long-term clinical trial. In contrast to acute studies, this study revealed that during long-term therapy mean weight increased. Effects on ECG parameters were consistent with increased heart rate. No evidence for a drug related QTc prolongation was observed."

        The research was funded by Lilly Research Laboratories.



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send